---
title: "UBS Reaffirms Their Hold Rating on Medartis Holding AG (MED)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279632894.md"
description: "UBS analyst Tanya Hansalik has reaffirmed a Hold rating on Medartis Holding AG (MED) with a price target of CHF92.00. The analyst focuses on the Healthcare sector and has an average return of -7.3% with an 18.18% success rate on stock recommendations. The consensus among analysts for Medartis Holding AG is also a Hold, with a price target of CHF92.00."
datetime: "2026-03-18T12:55:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279632894.md)
  - [en](https://longbridge.com/en/news/279632894.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279632894.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/279632894.md) | [繁體中文](https://longbridge.com/zh-HK/news/279632894.md)


# UBS Reaffirms Their Hold Rating on Medartis Holding AG (MED)

In a report released today, Tanya Hansalik from UBS maintained a Hold rating on Medartis Holding AG, with a price target of CHF92.00.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Hansalik covers the Healthcare sector, focusing on stocks such as Siegfried Holding AG, PolyPeptide Group AG, and Medartis Holding AG. According to TipRanks, Hansalik has an average return of \-7.3% and a 18.18% success rate on recommended stocks.

Medartis Holding AG has an analyst consensus of Hold, with a price target consensus of CHF92.00.

### Related Stocks

- [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [ProShares UltraShort Nasdaq Biotech (BIS.US)](https://longbridge.com/en/quote/BIS.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/en/quote/516820.CN.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/en/quote/560600.CN.md)
- [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/en/quote/588860.CN.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Stocks in Play: Ventripoint Diagnostics Ltd](https://longbridge.com/en/news/281544776.md)
- [07:03 ETSobi publishes Annual and Sustainability Report for 2025](https://longbridge.com/en/news/281174129.md)
- [02:10 ETAbbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children](https://longbridge.com/en/news/281132830.md)
- [09:00 ETDelonix Bioworks Announces Initiation of Phase 1 First-in-Human Clinical Trial of a Next-Generation MenB OMV Vaccine DX-104](https://longbridge.com/en/news/281025352.md)
- [Assessing BioArctic (OM:BIOA B) Valuation After New Lecanemab Data And Regulatory Milestones](https://longbridge.com/en/news/281644038.md)